A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs GS 0976 (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Gilead Sciences; Nimbus Therapeutics
  • Most Recent Events

    • 14 Apr 2018 Results presented at The International Liver Congress 2018.
    • 14 Apr 2018 Results of validation of biomarker metric for MRI-PDFF presented at The International Liver Congress 2018.
    • 14 Apr 2018 Results of response of controlled attenuation parameter and its correlation with MRI-proton density fat fraction presented at The International Liver Congress 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top